Evidence map›Paper›PMID 26995794›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2016

Smoking Topography Characteristics of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls.

Jennifer W Tidey, Rachel N Cassidy, Mollie E Miller

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Nicotine Reduction in Cigarettes: Literature Review and Gap Analysis.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Pooled it
  2. Trial
  3. Smoking Topography Characteristics During a 6-Week Trial of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020
    Trial
  4. Examining Age as a Potential Moderator of Response to Reduced Nicotine Content Cigarettes in Vulnerable Populations.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Trial
  5. Effects of 6-Week Use of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Trial
  6. Trial
  7. Trial
  8. Blood Nicotine Predicts the Behavioral Economic Abuse Liability of Reduced-Nicotine Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Article
  9. Review
  10. Article
  11. A Procedure to Standardize Puff Topography During Evaluations of Acute Tobacco or Electronic Cigarette Exposure.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020
    Article
  12. Potential Moderating Effects of Psychiatric Diagnosis and Symptom Severity on Subjective and Behavioral Responses to Reduced Nicotine Content Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Article
  13. Reducing the Nicotine Content of Cigarettes: Effects in Smokers With Mental Health Conditions and Socioeconomic Disadvantages.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Article
  14. Review
  15. The Effect of Price on the Consumption of Reduced Nicotine Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Animal Research on Nicotine Reduction: Current Evidence and Research Gaps.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jennifer W TideyCenter for Alcohol and Addiction Studies, Brown University, Providence, RI jennifer_tidey@brown.edu.
Rachel N CassidyCenter for Alcohol and Addiction Studies, Brown University, Providence, RI.
Mollie E MillerCenter for Alcohol and Addiction Studies, Brown University, Providence, RI.
Brown University · US

Funding

VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIAU54DA031659 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HECHT, STEPHEN S · 2011 to 2022
$64.7M
Vermont Center on Tobacco Regulatory ScienceP50DA036114 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HIGGINS, STEPHEN T · 2013 to 2017
$19.1M
Transdermal Nicotine and Bupropion-SR in SchizophrenicsR01DA014002 · NIDA · BROWN UNIVERSITY · PI TIDEY, JENNIFER W. · 2001 to 2009
$2.0M
Evaluation of Very Low Nicotine Content Cigarettes in Adolescent SmokersK01CA189300 · NCI · BROWN UNIVERSITY · PI CASSIDY, RACHEL N · 2014 to 2018
$897k
NCI NIH HHS K01 CA189300NIDA NIH HHS P50 DA036114NIDA NIH HHS R01 DA014002NIDA NIH HHS U54 DA031659
6 · The paper itself

Abstract

introductionReducing the nicotine content of cigarettes to a minimally addictive level has been proposed as a regulatory strategy for reducing tobacco dependence. However, smokers with schizophrenia (SS) may be prone to changing their smoking topography in efforts to compensate for the reduction in nicotine content. The aims of this study were to compare smoking topography characteristics of usual-brand and very low nicotine content (VLNC) cigarettes in SS and control smokers without psychiatric illness (CS), and to determine whether nicotine replacement reversed any changes in topography produced by VLNC cigarettes.

methodsUsing a within-subjects, counter-balanced design, SS (n = 27) and CS (n = 23) smoked usual brand cigarettes, VLNC cigarettes while wearing placebo patches (VLNC + PLA), or VLNC cigarettes while wearing transdermal nicotine patches totaling 42mg (VLNC + NIC) during 5-hour ad libitum smoking sessions. Cigarettes were smoked through topography measurement devices.

resultsAcross conditions, SS smoked more puffs per session and per cigarette, had higher cigarette volumes, and had shorter inter-puff intervals than CS (Ps < .01). During VLNC cigarette sessions, puff duration increased and time between puffs decreased, but participants smoked fewer puffs, resulting in a net decrease in cigarette and total session volume (Ps < .001). There were no significant interactions between group and condition.

conclusionsThese findings indicate that acute use of VLNC cigarettes does not increase intensity of smoking in SS, and support the feasibility of a nicotine reduction policy. IMPLICATIONS: Reducing the nicotine in cigarettes to a minimally addictive level has been proposed as a means of reducing tobacco dependence. However, smokers, particularly those with schizophrenia (SS) may alter their puffing in an attempt to extract more nicotine from VLNC cigarettes. This study compared smoking topography of usual brand versus VLNC cigarettes, combined with placebo or transdermal nicotine patches, in SS and controls. Although some changes in topography were indicative of compensatory smoking, total puffs and total cigarette volume were reduced with VLNC cigarettes, indicating that acute VLNC cigarette use does not increase smoking in SS.

Indexed as

Behavior, AddictiveSchizophreniaAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedNicotineSmokingSmoking CessationSmoking PreventionTobacco Use Cessation DevicesNicotine

Identifiers

PMID26995794
PMCPMC4978982
OpenAlexW2307504991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.